

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1 to 7. (canceled)

Claim 8. (currently amended) A method of treating a disease of a posterior segment of an eye comprising administering subconjunctivally to a patient an effective amount for treatment of an injection comprising fine particles containing a drug and enabling the concentration of the drug in a retina-choroid to be sustained, ~~wherein~~ the disease of the posterior segment of the eye ~~is being~~ uvetis, cytomegalovirus retinitis, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy or retinal detachment, the fine particles containing the drug being a matrix-type, wherein the drug is dispersed uniformly in the fine particles, and a particle diameter of the fine particles ~~is being~~ 50 nm to 150 μ m.

Claim 9. (canceled)

Claim 10. (previously presented) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a biodegradable or biosoluble polymer.

Claim 11. (canceled)

Claim 12. (previously presented) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the drug is betamethasone, dexamethasone, triamcinolone or prednisolone.

Claims 13 to 17. (canceled)

Claim 18. (new) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are produced by a submerged drying method.

Claim 19. (new) The method of treating the disease of the posterior segment of the eye as claimed in claim 8, wherein the fine particles are made of a polylactic acid having a weight-average molecular weight of 20,000, and the drug is betamethasone.